| REGISTERED NUMBER: |
| UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026 |
| FOR |
| MATRIX PHARMACY LIMITED |
| REGISTERED NUMBER: |
| UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026 |
| FOR |
| MATRIX PHARMACY LIMITED |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| CONTENTS OF THE FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 4 |
| MATRIX PHARMACY LIMITED |
| COMPANY INFORMATION |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| ACCOUNTANTS: |
| 2 Cedargrove |
| Hagley |
| Stourbridge |
| West Midlands |
| DY9 0DR |
| BANKERS: |
| 293 High Street |
| West Bromwich |
| West Midlands |
| B70 8NA |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| BALANCE SHEET |
| 31 MARCH 2026 |
| 2026 | 2025 |
| Notes | £ | £ |
| FIXED ASSETS |
| Intangible assets | 4 |
| Tangible assets | 5 |
| Investments | 6 |
| CURRENT ASSETS |
| Stocks | 7 |
| Debtors | 8 |
| Cash at bank and in hand |
| CREDITORS |
| Amounts falling due within one year | 9 | ( |
) | ( |
) |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CREDITORS |
| Amounts falling due after more than one year |
10 |
( |
) |
( |
) |
| PROVISIONS FOR LIABILITIES | 14 | ( |
) | ( |
) |
| NET ASSETS |
| CAPITAL AND RESERVES |
| Called up share capital | 15 |
| Share premium | 16 |
| Retained earnings | 16 |
| SHAREHOLDERS' FUNDS |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| BALANCE SHEET - continued |
| 31 MARCH 2026 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 1. | STATUTORY INFORMATION |
| Matrix Pharmacy Limited is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Goodwill |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
| Tangible fixed assets |
| Improvements to property | - |
| Fixtures, fittings & equipment | - |
| Investments in subsidiaries |
| Investments in subsidiary undertakings are recognised at cost. |
| Stocks |
| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 2. | ACCOUNTING POLICIES - continued |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Hire purchase and leasing commitments |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | INTANGIBLE FIXED ASSETS |
| Goodwill |
| £ |
| COST |
| At 1 April 2025 |
| and 31 March 2026 |
| AMORTISATION |
| At 1 April 2025 |
| Amortisation for year |
| At 31 March 2026 |
| NET BOOK VALUE |
| At 31 March 2026 |
| At 31 March 2025 |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 5. | TANGIBLE FIXED ASSETS |
| Improvements | Fixtures, |
| Short | to | fittings |
| leasehold | property | & equipment | Totals |
| £ | £ | £ | £ |
| COST |
| At 1 April 2025 |
| Additions |
| At 31 March 2026 |
| DEPRECIATION |
| At 1 April 2025 |
| Charge for year |
| At 31 March 2026 |
| NET BOOK VALUE |
| At 31 March 2026 |
| At 31 March 2025 |
| 6. | FIXED ASSET INVESTMENTS |
| Shares in |
| group |
| undertakings |
| £ |
| COST |
| Additions |
| At 31 March 2026 |
| NET BOOK VALUE |
| At 31 March 2026 |
| The company's investments at the Balance Sheet date in the share capital of companies include the following: |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 6. | FIXED ASSET INVESTMENTS - continued |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF |
| Nature of business: |
| % |
| Class of shares: | holding |
| 2026 |
| £ |
| Aggregate capital and reserves |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 7. | STOCKS |
| 2026 | 2025 |
| £ | £ |
| Stocks |
| 8. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Trade debtors |
| Amounts owed by group undertakings |
| Other debtors |
| VAT |
| Prepayments and accrued income |
| 9. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Bank loans and overdrafts (see note 11) |
| Trade creditors |
| Amounts owed to group undertakings |
| Corporation tax |
| Social security and other taxes |
| Other creditors |
| Accruals and deferred income |
| 10. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Bank loans (see note 11) |
| Amounts falling due in more than five years: |
| Repayable by instalments |
| Bank loans more 5 yr by instal | 18,582 | 99,113 |
| 11. | LOANS |
| An analysis of the maturity of loans is given below: |
| 2026 | 2025 |
| £ | £ |
| Amounts falling due within one year or on demand: |
| Bank loans |
| Amounts falling due between one and two years: |
| Bank loans - 1-2 years |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 11. | LOANS - continued |
| 2026 | 2025 |
| £ | £ |
| Amounts falling due between two and five years: |
| Bank loans - 2-5 years |
| Amounts falling due in more than five years: |
| Repayable by instalments |
| Bank loans more 5 yr by instal | 18,582 | 99,113 |
| 12. | LEASING AGREEMENTS |
| Minimum lease payments under non-cancellable operating leases fall due as follows: |
| 2026 | 2025 |
| £ | £ |
| In more than five years |
| 13. | SECURED DEBTS |
| The following secured debts are included within creditors: |
| 2026 | 2025 |
| £ | £ |
| Bank loans |
| 14. | PROVISIONS FOR LIABILITIES |
| 2026 | 2025 |
| £ | £ |
| Deferred tax | 84,594 | 74,717 |
| Deferred |
| tax |
| £ |
| Balance at 1 April 2025 |
| Charged during the year | 9,877 |
| Balance at 31 March 2026 |
| 15. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2026 | 2025 |
| value: | £ | £ |
| Ordinary | £1 | 8 | 8 |
| MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 MARCH 2026 |
| 16. | RESERVES |
| Retained | Share |
| earnings | premium | Totals |
| £ | £ | £ |
| At 1 April 2025 | 2,413,308 |
| Profit for the year |
| Dividends | ( |
) | ( |
) |
| At 31 March 2026 | 2,490,953 |
| 17. | RELATED PARTY DISCLOSURES |
| At 31 March 2026, there was a loan from Matrix Primary Healthcare Limited of £156,548 (2025: £57,421), a company in which Mr P Hargun and Mr A Singh are directors. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan to Matrix Asset Holdings Limited of £379,233 (2025: £268,153), a company in which Mr P Hargun and Mr A Singh are directors. Matrix Asset Holdings Limited is the parent undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Wootton Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Wootton Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Tudor Hope Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Tudor Hope Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Instore Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Instore Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Thornbury Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Thornbury Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Areley Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Areley Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| At 31 March 2026, there was a loan from Alveston Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Alveston Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand. |
| 18. | ULTIMATE CONTROLLING PARTY |
| The controlling party is Matrix Asset Holdings Limited. |